Literature DB >> 21317204

Androgen receptor levels are upregulated by Akt in prostate cancer.

Susan Ha1, Rachel Ruoff, Nicole Kahoud, Thomas F Franke, Susan K Logan.   

Abstract

Multiple lines of evidence suggest a functional link between the androgen receptor (AR) and the serine/threonine kinase Akt in the development and progression of prostate cancer. To investigate the impact of Akt activity on AR homeostasis, we treated androgen-dependent LNCaP and LAPC-4 prostate cancer cells with Akt inhibitor. Akt inhibition decreased AR expression, suggesting that Akt activity was required for regulation of AR protein levels. However, while androgen-independent LNCaP-abl cells also showed diminished AR protein levels in response to Akt inhibition, treatment of androgen-independent LNCaP-AI cells failed to alter AR protein levels upon similar treatment, suggesting that AR protein levels in these androgen-independent prostate cells were regulated by mechanisms independent of Akt activation. Regulation of AR, downstream of activated Akt, also was observed in vivo when examining transgenic mice that overexpress constitutively active mutant myristoylated (myr)-Akt1 in the prostate. Transgenic mice expressing activated myr-Akt1 exhibited higher levels of AR mRNA and protein. Expression of activated myr-Akt1 did not alter prostate cell growth and no significant size differences between prostate tissues derived from transgenic animals were observed when comparing transgenic mice with wild-type mice. Still, transgenic mice overexpressing Akt exhibited higher levels of γH2AX and phosphorylated Chk2 in prostate tissue. These changes in markers associated with oncogene-induced senescence confirmed significant altered signaling in the transgenic mouse model. Overall, results presented here suggest that AR levels are regulated by the Akt pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317204      PMCID: PMC3674416          DOI: 10.1530/ERC-10-0204

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  36 in total

1.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

Authors:  Craig W Lindsley; Zhijian Zhao; William H Leister; Ronald G Robinson; Stanley F Barnett; Deborah Defeo-Jones; Raymond E Jones; George D Hartman; Joel R Huff; Hans E Huber; Mark E Duggan
Journal:  Bioorg Med Chem Lett       Date:  2005-02-01       Impact factor: 2.823

2.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.

Authors:  Pradip K Majumder; Jen Jen Yeh; Daniel J George; Phillip G Febbo; Jennifer Kum; Qi Xue; Rachel Bikoff; Hongfeng Ma; Philip W Kantoff; Todd R Golub; Massimo Loda; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

Review 3.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

4.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

5.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

6.  Identification of prostate cancer modifier pathways using parental strain expression mapping.

Authors:  Qing Xu; Pradip K Majumder; Kenneth Ross; Yeonju Shim; Todd R Golub; Massimo Loda; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-31       Impact factor: 11.205

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines.

Authors:  Sandra Koseoglu; Zhuomei Lu; Chandra Kumar; Paul Kirschmeier; Jun Zou
Journal:  Cancer Biol Ther       Date:  2007-02-09       Impact factor: 4.742

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients.

Authors:  C Le Page; I H Koumakpayi; M Alam-Fahmy; A-M Mes-Masson; F Saad
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

View more
  32 in total

1.  Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less.

Authors:  Bo Li; Wenfu Lu; Zhenbang Chen
Journal:  Receptors Clin Investig       Date:  2014

2.  Androgen receptor promotes esophageal cancer cell migration and proliferation via matrix metalloproteinase 2.

Authors:  Yi Zhang; Tiecheng Pan; Xiaoxuan Zhong; Cai Cheng
Journal:  Tumour Biol       Date:  2015-02-28

3.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Authors:  Ziyang Yu; Sen Chen; Adam G Sowalsky; Olga S Voznesensky; Elahe A Mostaghel; Peter S Nelson; Changmeng Cai; Steven P Balk
Journal:  Clin Cancer Res       Date:  2014-01-21       Impact factor: 12.531

4.  Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.

Authors:  Remi Adelaiye-Ogala; Nur P Damayanti; Ashley R Orillion; Sreevani Arisa; Sreenivasulu Chintala; Mark A Titus; Chinghai Kao; Roberto Pili
Journal:  Cancer Res       Date:  2018-03-23       Impact factor: 12.701

5.  Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Authors:  Michael A Gordon; Nicholas C D'Amato; Haihua Gu; Beatrice Babbs; Julia Wulfkuhle; Emanuel F Petricoin; Isela Gallagher; Ting Dong; Kathleen Torkko; Bolin Liu; Anthony Elias; Jennifer K Richer
Journal:  Mol Cancer Ther       Date:  2017-05-03       Impact factor: 6.261

6.  Aging impairs VEGF-mediated, androgen-dependent regulation of angiogenesis.

Authors:  Laura Lecce; Yuen Ting Lam; Laura A Lindsay; Sui Ching Yuen; Philippa J L Simpson; David J Handelsman; Martin K C Ng
Journal:  Mol Endocrinol       Date:  2014-07-24

7.  ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Authors:  Shuai Gao; Huihui Ye; Sean Gerrin; Hongyun Wang; Ankur Sharma; Sen Chen; Akash Patnaik; Adam G Sowalsky; Olga Voznesensky; Wanting Han; Ziyang Yu; Elahe A Mostaghel; Peter S Nelson; Mary-Ellen Taplin; Steven P Balk; Changmeng Cai
Journal:  Clin Cancer Res       Date:  2016-03-02       Impact factor: 12.531

8.  Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.

Authors:  Thirupandiyur S Udayakumar; Radka Stoyanova; Mohammed M Shareef; Zhaomei Mu; Sakhi Philip; Kerry L Burnstein; Alan Pollack
Journal:  Mol Cancer Ther       Date:  2016-03-04       Impact factor: 6.261

9.  Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.

Authors:  Bo Li; Wenfu Lu; Qing Yang; Xiuping Yu; Robert J Matusik; Zhenbang Chen
Journal:  Prostate       Date:  2013-12-17       Impact factor: 4.104

10.  Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus.

Authors:  Pooja Gupta-Saraf; Tyler Meseke; Cathy L Miller
Journal:  Virology       Date:  2015-08-08       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.